Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1805 results
September 2023
-
Key ReleaseSandoz veröffentlicht Nachtrag zum Kotierungsprospekt, einschliesslich Finanzabschluss von Sandoz für das 1. Halbjahr 2023Ad-hoc-Mitteilung gemäss Art. 53 LRNachtrag von Sandoz veröffentlicht vor der ausserordentlichen Generalversammlung von Novartis am 15. September 2023Die Ergebnisse des ersten…
-
StatementNovartis statement on filing of Inflation Reduction Act lawsuit
August 2023
-
StatementNovartis statement about Entresto® (sacubitril/valsartan) selection for Medicare Drug Price Negotiation Program
-
Media ReleaseNovartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six yearsResults from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-C) reduction beyond six…
-
Media ReleaseSandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolioSandoz completes acquisition of worldwide brand rights for Mycamine® (micafungin sodium) from Astellas Leading global echinocandin, one of three major antifungal classes, will significantly…
-
Media ReleaseSandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosisBiosimilar Tyruko® approved for all indications of reference medicine, with same dosing and administration schedule Sandoz continues to expand access to much-needed medications for patients…
-
Key ReleaseNovartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off voteAd hoc announcement pursuant to Art. 53 LR Invitation to Novartis Extraordinary General Meeting on September 15, 2023, and Shareholder Information Brochure issuedSandoz Listing Prospectus…
-
Key ReleaseNovartis publiziert Einladung und Aktionärsbroschüre zur ausserordentlichen Generalversammlung. Sandoz veröffentlicht den Kotierungsprospekt im Vorfeld der Abstimmung zum vorgeschlagenen Spin-offAd-hoc-Meldung nach Art. 53 LR Einladung zur ausserordentlichen Generalversammlung von Novartis am 15. September 2023 und Informationsbroschüre für Aktionärinnen und Aktionäre publiziertSandoz…
-
Key ReleaseNovartis publie l’invitation à l’AGE et la brochure d’information aux actionnaires. Sandoz publie le prospectus de cotation avant le vote sur la proposition de scissionAnnonce ad hoc en vertu de l’art. 53 LR Invitation à l’assemblée générale extraordinaire de Novartis du 15 septembre 2023 et publication d’une brochure d’information destinée…
-
Media ReleaseSandoz announces positive results from Mylight Phase lll study for biosimilar afliberceptMylight study met its primary efficacy endpoint and showed no clinically meaningful differences to reference afliberceptResults offer hope of new affordable option for patients with nAMD, a leading…
-
Media ReleaseNovartis completes acquisition of Chinook TherapeuticsAcquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfrontDeal brings two phase 3 assets in development for IgAN; atrasentan, an oral endothelin…
-
Key ReleaseNovartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaAd hoc announcement pursuant to Art. 53 LR The Phase III REMIX-1 and REMIX-2 studies met all primary and secondary endpoints, showing rapid, clinically meaningful improvements across…
Pagination
- ‹ Previous page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- …
- 151
- › Next page